Hikma Pharmaceuticals Plc - Company Profile
Powered by
All the data and insights you need on Hikma Pharmaceuticals Plc in one report.
- Save hours of research time and resources with
our up-to-date Hikma Pharmaceuticals Plc Strategy Report
- Understand Hikma Pharmaceuticals Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hikma Pharmaceuticals Plc Catalyst Calendar
Proactively evaluate Hikma Pharmaceuticals Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Hikma Pharmaceuticals Plc Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
05 Feb 2023 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
01 Aug 2022 | Phase IV Trial Initiation | Hikma Pharmaceuticals LLC | - | imatinib mesylate | Oncology | Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) | Clinical Trial Registry |
10 Feb 2022 | Phase I Trial Initiation | Hikma Pharmaceuticals Plc; International Pharmaceutical Research Center; Invitro Research Solutions Pvt Ltd | HIK | cladribine | Central Nervous System | Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS) | Clinical Trial Registry |
01 Jan 2021 | Phase IV Trial Initiation | Hikma Pharmaceuticals Plc | HIK | Sclera | Central Nervous System | Relapsing Remitting Multiple Sclerosis (RRMS) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer